CLINICAL_TRIALS
trial_result
· 2021-08-12
Clinical Trial Update: Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 2]
Summary
Phase 2 trial assessing safety and efficacy of PDR001 in recurrent or metastatic nasopharyngeal carcinoma has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-12